explore -WSS

explore

author：fashion 2025-09-28 02:30:33 - browse：99331

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Massive project maps cells in human brain in unprecedented detail

WSS

Hubble vs. James Webb telescope images: See the difference

Eight reasons why you should get an updated Covid vaccine

Medicare to cover more brain scans related to Alzheimer’s drugs

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Drug cartel violence flares in western Mexico after vigilante leader's killing

Life sciences deals on track to hit lowest point since 2017

hotspot

explore

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How doctors and nurses shape Google's AI

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How Robert F. Kennedy Jr. distorted vaccine science

Dobbs anniversary: the lost opportunity of abortion as health care

How doctors and nurses shape Google's AI

Moonlake's readout produced a cash windfall. Risks remain

Better Therapeutics data on benefit with GLP

Malaria cases in Florida and Texas: Here’s what you need to know

Undocumented workers face uncertainty as immigration law takes effect in Florida

hotspot

'Screen and refer' systems are hurting patients

What the Wegovy shortage looks like for doctors — and for patients

Takeaways from AdvaMed, the largest medical devices conference

Medicare to cover more brain scans related to Alzheimer’s drugs

AstraZeneca lung cancer study comes in below expectations

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

hotspot

leisure time

focus

hotspot